A phase I trial assessing a 68Ga-sdAb conjugate targeting HER2 in 20 breast cancer patients highlighted the favorable biodistribution profile, safety, and tolerability of sdAb radioconjugates for diagnostic purposes, leading to a phase II trial in breast cancer patients with brain metastases (NCT03331601) (2). Here, ERBB2 is linked to breast carcinoma.